14 Jan 2016 –- Based on a strong start to the year, Chr Hansen expect organic revenue growth of 9-11% while the EBIT margin before special items is still expected to be above the 27.1% achieved in 2014/15. “We continue to implement our Nature's No 1 strategy, and I'm very pleased with the progress. We have signed an agreement to acquire Nutrition Physiology Company, which expand our current activities in animal health, and we have entered into our first commercial partnership in the human microbiome initiative,” states CEO, Cees de Jong.
